{
    "clinical_study": {
        "@rank": "4768", 
        "arm_group": [
            {
                "arm_group_label": "Maalox Plus extra", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive doses of raltegravir 400 mg and maalox plus extra"
            }, 
            {
                "arm_group_label": "Multivitamin", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive doses of raltegravir 400 mg along with a multivitamin tablet"
            }, 
            {
                "arm_group_label": "Sodium bicarbonate", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive doses of raltegravir 400 mg along with sodium bicarbonate"
            }
        ], 
        "brief_summary": {
            "textblock": "This study seeks to address the question of whether antacids or multivitamins influence the\n      pharmacokinetics of raltegravir when co-administered. The aim of this study is to optimise\n      the dosing of raltegravir when co-administered with antacids or multivitamins."
        }, 
        "brief_title": "The Effect of Antacids and Multivitamins on Raltegravir", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The ability to understand and sign a written informed consent form, prior to\n             participation in any screening procedures and must be willing to comply with all\n             study requirements.\n\n          -  \u2265 18 years\n\n          -  Male or female subjects\n\n          -  A female may be eligible to enter and participate in the study if she:\n\n          -  Is of non-child-bearing potential defined as ether post-menopausal (12 months of\n             spontaneous amenorrhea and \u2265 45 years of age)or physically incapable of becoming\n             pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or\n\n          -  Is of child-bearing potential with a negative pregnancy test at screening and agrees\n             to use one of the following methods of contraception to avoid pregnancy\n\n          -  Complete abstinence from intercourse from 2 weeks prior to administration of IP,\n             throughout the study and for at least 4 weeks after discontinuation of all study\n             medication\n\n          -  Double barrier method (male condom/spermicide, male condom/diaphragm,\n             diaphragm/spermicide)\n\n          -  Any intrauterine device (IUD) with published data showing that the expected failure\n             rate is < 1 % per year\n\n          -  Any other method with published data showing that the expected failure rate is < 1 %\n             per year\n\n          -  Hormonal contraception plus a barrier method.  Hormonal contraception alone will not\n             be considered adequate for inclusion into or participation in this study\n\n          -  Male subjects with a female partner of childbearing potential must agree to use\n             effective contraception as above unless vasectomized\n\n          -  All subjects participating in the study will be counseled on safer sexual practices\n             including the use of effective barrier methods (e.g. male condom)\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical condition\n\n          -  Pregnant or lactating women\n\n          -  Women of childbearing age unless using non hormonal contraception\n\n          -  Evidence of organ dysfunction or any clinically significant deviation from normal\n             during screening including laboratory determinations\n\n          -  Abnormal LFTs (ALT > 2.5 x ULN, bilirubin > 1.5 x ULN)\n\n          -  Positive blood screen for HIV-1 and 2 antibodies\n\n          -  Positive blood screen for hepatitis B or C antibodies\n\n          -  Current or recent (within 3 months) gastrointestinal disease\n\n          -  Clinically relevant alcohol or drug use or history of alcohol or drug use that will\n             hinder compliance with treatment, follow up procedures or evaluation of adverse\n             effects\n\n          -  Use of proton pump inhibitors\n\n          -  Exposure to any investigational drug or placebo within 4 weeks of first dose of study\n             drug\n\n          -  Consumption of grapefruit and oranges or products containing grapefruit or oranges\n             within 1 week of first study drug and for the duration of the study\n\n          -  Use of any other drugs including over-the-counter medications and herbal\n             preparations, within 2 weeks prior to first dose of study drug\n\n          -  Previous allergy to any of the constituents of the pharmaceuticals in this trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784302", 
            "org_study_id": "4347"
        }, 
        "intervention": [
            {
                "arm_group_label": "Multivitamin", 
                "intervention_name": "Multivitamins", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Sodium bicarbonate", 
                "intervention_name": "Sodium bicarbonate", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Maalox Plus extra", 
                "intervention_name": "Maalox Plus extra", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Maalox Plus extra", 
                    "Multivitamin", 
                    "Sodium bicarbonate"
                ], 
                "intervention_name": "Raltegravir 400 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antacids", 
                "Aluminum hydroxide, magnesium hydroxide, simethicone drug combination", 
                "Aluminum hydroxide, magnesium hydroxide, drug combination", 
                "TEMPO"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Liverpool", 
                    "country": "United Kingdom", 
                    "zip": "L7 8XP"
                }, 
                "name": "Royal Liverpool University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A 3 Arm, 5 Phase Study to Determine the Effect of Divalent and Monovalent Metal Containing Antacids and Multivitamins on the Pharmacokinetics of Raltegravir in Healthy Volunteers", 
        "overall_contact": {
            "email": "her@liv.ac.uk", 
            "last_name": "Helen Reynolds"
        }, 
        "overall_contact_backup": {
            "email": "IDResearch@rlbuht.nhs.uk", 
            "last_name": "Research Nurse"
        }, 
        "overall_official": {
            "affiliation": "University of Liverpool", 
            "last_name": "Saye Khoo, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint will be a change in raltegravir AUC0-12 h, following dosing of antacid or multivitamin", 
            "measure": "Change in raltegravir Area under the curve (AUC)0-12h", 
            "safety_issue": "No", 
            "time_frame": "Day 1, 6, 11, 16 and 21"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784302"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Liverpool", 
            "investigator_full_name": "Helen Reynolds", 
            "investigator_title": "Research nurse", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Correlation between gastric pH and raltegravir pharmacokinetics", 
                "measure": "Measurement of gastrointestinal pH", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 6, 11, 16 and 21"
            }, 
            {
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 up to end of study Day 27"
            }
        ], 
        "source": "University of Liverpool", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Helen Reynolds", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}